Ventric Health, maker of the Vivio System — the only FDA-cleared non-invasive device for measuring elevated left ventricular end-diastolic pressure — has appointed Javed Butler, MD, MPH, MBA, and Biykem Bozkurt, MD, PhD, to its Clinical Advisory Board. The appointments are designed to reinforce Ventric Health’s commitment to clinical excellence as the company scales the commercial expansion of the Vivio System into primary care, cardiology, and other outpatient healthcare environments. As leaders in cardiovascular medicine with decades of experience in diagnosing, treating, and managing complex heart failure, both physicians bring the kind of clinical credibility that is essential for a medical device company working to reshape how heart failure is detected and managed in outpatient settings.
Dr. Butler is President of the Baylor Scott and White Research Institute and Senior Vice President at Baylor Scott and White Health. He is also a Distinguished Professor of Medicine at the University of Mississippi and holds the Maxwell A. and Gayle H. Clampitt Endowed Chair. A fellow of the Heart Failure Society of America, the European Society of Cardiology, the American College of Cardiology, and the American Heart Association, Dr. Butler has authored over 1,500 peer-reviewed publications and serves on the editorial boards of several leading cardiovascular journals. His extensive research output and institutional leadership make him one of the most recognized figures in heart failure medicine globally.
Dr. Bozkurt is Editor-in-Chief of JACC Journals: Heart Failure and serves as the Mary and Gordon Cain Chair and professor of medicine at Baylor College of Medicine, as well as director of the Winters Center for Heart Failure Research and associate director of the Cardiovascular Research Institute. She also holds roles as associate provost of faculty affairs, senior associate dean for faculty development, and vice-chair of Medicine at Baylor. A past president of the Heart Failure Society of America, Dr. Bozkurt’s leadership across clinical care, research, and academic medicine reflects a career dedicated to advancing the field of heart failure from multiple angles.
The Vivio System measures left ventricular end diastolic pressure non-invasively using a physics-based analysis of cardiac pressure and volume waveforms, completing the test in under five minutes at the point of care without imaging, referral, or invasive procedures. Published evidence includes a 2025 multicenter JAHA validation study, a 2025 HFSA abstract on pre-symptomatic Stage A detection, and a JACC Advances study on primary care screening. Dr. Butler and Dr. Bozkurt join existing advisors including Dr. KellyAnn Light-McGroary, Dr. John Spertus, and Erik Abel, PharmD, on a board united by the goal of ensuring that the Vivio System remains aligned with real-world care pathways.
KEY QUOTES:
“Welcoming two such distinguished cardiologists as advisors to our team is a testament to the clinical impact of the Vivio System. Their deep understanding of the patient journey and the limitations of traditional diagnostic tools will be invaluable. They will help us ensure that Vivio not only meets the highest clinical standards but also seamlessly integrates into modern primary care and cardiology workflows to close the gap in heart failure detection and treatment.”
Sean Brady, CEO, Ventric Health
